Loading...
XHEL
ORNAV
Market cap9.78bUSD
Dec 04, Last price  
59.90EUR
1D
-0.66%
1Q
-8.83%
Jan 2017
41.34%
IPO
334.06%
Name

Orion Oyj

Chart & Performance

D1W1MN
XHEL:ORNAV chart
P/E
25.53
P/S
5.46
EPS
2.35
Div Yield, %
2.70%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
7.98%
Revenues
1.54b
+29.66%
1,901,800,000311,200,000683,600,000710,700,000771,500,000849,900,000917,900,000980,300,0001,006,900,0001,015,300,0001,015,600,0001,073,500,0001,084,700,000977,400,0001,050,900,0001,078,100,0001,041,000,0001,340,700,0001,189,600,0001,542,400,000
Net income
330m
+52.17%
131,100,00066,600,000145,400,000136,300,000151,400,000184,700,000209,500,000208,900,000206,200,000211,300,000208,200,000249,000,000226,000,000330,300,000200,400,000219,900,000193,800,000349,500,000216,800,000329,900,000
CFO
293m
+146.55%
173,300,00081,600,000150,900,000144,400,000204,600,000209,100,000198,900,000221,000,000215,200,000296,700,000254,900,000249,100,000228,400,000230,900,000270,800,000299,100,000215,700,000434,400,000119,000,000293,400,000
Dividend
Oct 15, 20250.82 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
URL
https://www.orion.fi/
IPO date
Jul 03, 2006
Employees
3,657
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT